Cytarabine and Squamous cell carcinoma - a phase IV clinical study of FDA data

Summary:

Squamous cell carcinoma is reported as a side effect among people who take Cytarabine (cytarabine), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Bicnu, and have B-cell lymphoma recurrent.

The phase IV clinical study analyzes which people have Squamous cell carcinoma when taking Cytarabine. It is created by eHealthMe based on reports of 65,319 people who have side effects when taking Cytarabine from the FDA, and is updated regularly.

What is Cytarabine?

Cytarabine has active ingredients of cytarabine. It is often used in acute myelogenous leukemia (aml) - adult. eHealthMe is studying from 65,358 Cytarabine users. Check the latest studies of Cytarabine.

What is Squamous cell carcinoma?

Squamous cell carcinoma (a cancer of a kind of epithelial cell) is found to be associated with 812 drugs and 897 conditions by eHealthMe. Check the latest studies of Squamous cell carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 31, 2026

65,319 people reported to have side effects when taking Cytarabine.
Among them, 42 people (0.06%) have Squamous cell carcinoma.

Could Cytarabine cause Squamous cell carcinoma?

Among these 42 people:

How long have people been on Cytarabine when they have Squamous cell carcinoma? *

  • < 1 month: 44.44 %
  • 1 - 6 months: 55.56 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Squamous cell carcinoma when taking Cytarabine? *

  • female: 54.17 %
  • male: 45.83 %

What is the age of people who have Squamous cell carcinoma when taking Cytarabine? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 4.35 %
  • 20-29: 30.43 %
  • 30-39: 0.0 %
  • 40-49: 4.35 %
  • 50-59: 0.0 %
  • 60+: 60.87 %

What are other drugs people take besides Cytarabine? *

  1. Bicnu: 14 people, 33.33%
  2. Methotrexate: 6 people, 14.29%
  3. Cyclophosphamide: 5 people, 11.90%
  4. Thioguanine: 5 people, 11.90%
  5. Fludarabine Phosphate: 4 people, 9.52%
  6. Fludara: 3 people, 7.14%
  7. Itraconazole: 3 people, 7.14%
  8. Neupogen: 3 people, 7.14%
  9. Etoposide: 3 people, 7.14%
  10. Lenalidomide: 3 people, 7.14%

What are other side effects people have besides Squamous cell carcinoma? *

  1. Fatigue (feeling of tiredness): 18 people, 42.86%
  2. Basal Cell Carcinoma (a skin cancer, it rarely metastasizes or kills): 18 people, 42.86%
  3. Interstitial Lung Disease: 17 people, 40.48%
  4. Fungal Infection: 17 people, 40.48%
  5. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 17 people, 40.48%
  6. Depression: 16 people, 38.10%
  7. Lung Cancer - Non-Small Cell (lung cancer): 16 people, 38.10%
  8. Idiopathic Pulmonary Fibrosis (chronic lung disease): 16 people, 38.10%
  9. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 16 people, 38.10%
  10. Herpes Zoster: 16 people, 38.10%

What are the existing conditions these people have? *

  1. B-Cell Lymphoma Recurrent (blood cancer affecting b cells-recurrent): 14 people, 33.33%
  2. B-Cell Lymphoma Refractory (blood cancer affecting b cells-relapsed): 12 people, 28.57%
  3. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 11 people, 26.19%
  4. Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 5 people, 11.90%
  5. Burkitt Lymphoma (cancer of the lymphatic system): 3 people, 7.14%
  6. Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 2 people, 4.76%
  7. Skin Cancer: 1 person, 2.38%
  8. Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 1 person, 2.38%
  9. Osteopenia (a condition where bone mineral density is lower than normal): 1 person, 2.38%
  10. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Cytarabine and have Squamous cell carcinoma?

- Check whether Squamous cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cytarabine:

Squamous cell carcinoma treatments and more:

How severe was Squamous cell carcinoma and when was it recovered:

Expand to all the drugs that have ingredients of cytarabine:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cytarabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Squamous cell carcinoma:

Browse all the conditions that are associated with Squamous cell carcinoma:


How the study uses the data?

The study uses data from the FDA. It is based on cytarabine (the active ingredients of Cytarabine) and Cytarabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: